Search

Recycled aggregate concrete has received much attention in recent years. Using tailings sand in concrete can save natural resources and create environmentally friendly building materials. Simultaneously, adding iron tailings can compensate for the loss of strength caused by recycled aggregates and enhance performance. The mechanical properties of recycled aggregate concrete with iron tailings and prepared concrete specimens with iron tailings sand content of 0%, 25%, 50%, 75%, and 100% were studied. Mechanical tests are conducted to evaluate the performance with the assistance of PVA fibers. The patterns of change in numerical values such as compressive strength, flexural strength, and peak strain of recycled concrete specimens are tested and analyzed, and the experiment's effectiveness is demonstrated through finite element numerical simulation. The results show that when the TRAC content is 50%, the working performance of recycled concrete reaches its peak; When the TRAC content exceeds 50%, the positive effect of tailings sand on the performance of concrete decreases; The strength of TRAC concrete increases with the increase of PVA fiber content; Improving the replacement rate of recycled iron tailings aggregate can increase the peak strain of the specimen under cyclic loading, and the stress-strain curve calculated by finite element software is consistent with the experimental results.

To study the effect of Trastuzumab in combination with IFN α-2b on HER2 and MRP1 of ACHNin vitro, ACHN cell line of RCC was cultured by employing cell culture. The tetrazolium-based colorimetric assay was used to evaluate the growth-inhibiting effect of Trastuzumab with IFN α-2b. SP method was utilized to determine the expression of HER2 and MRP1 of the cells. Our results showed that Trastuzumab had inhibitory effect on the growth of renal tumor cells and reversing effect on the multi-drug-resistance (MDR) in RCC in a time- and dose-dependent manner. Treated with Trastuzumab with or without IFN α-2b, the expression of HER2 and MRP1 genes of RCC was decreased significantly (P<0.05). It was concluded that Trastuzumab with IFN α-2b could inhibit the proliferation of RCC and the expression of HER2 and MRP1 of ACHN and to some extent, reverse the MDR of the tumor cells.